 Brickell Biotech NASDAQ: BBI shares are trading lower after the company announced a bought deal offering of common stock of 5 million, which was later increased to 7 million. Brickell Biotech is a clinical-stage pharmaceutical company that focuses on identifying, developing, and commercialising various prescription therapeutics for the treatment of debilitating skin diseases in the United States. 